From Surf Wiki (app.surf) — the open knowledge base
Buflomedil
Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.
Toxicity
This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity. In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.
Various adverse effects have been reported to the FDA.
Synthesis
Acylation between 1,3,5-trimethoxybenzene [621-23-8] (1) and 4-pyrrolidinobutyronitrile [35543-25-0] (2) occurs in chlorobenzene solvent in the presence of gaseous hydrochloric acid to give Bufomedil (3). This is a demonstration of the Hoesch reaction.
References
References
- "Buflomedil-Containing Drugs May Be Suspended in EU". Medscape.
- link. (23 January 2012)
- (February 2012). "Buflomedil durchf beschluss".
- "Drug cite".
- DE2122144 idem Louis Lafon, {{US patent. 3895030 (1975 to Orsymonde);
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Buflomedil — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report